CTLA4 and metastatic melanoma: In metastatic melanoma patients and mouse models, SCFAs (butyrate and propionate) limit the antitumor effects of CTLA-4 inhibitors via inducing CTLA-4 blocking resistance and a high proportion of Tregs.